An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
NCT02182206
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Tumors
Interventions
DRUG:
BIBF 1120
Sponsor
Boehringer Ingelheim